Argos Therapeutics
13
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
76.9%
-9.6% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
Role: collaborator
A Rollover Protocol for Subjects Previously Treated With AGS-003
Role: lead
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Role: lead
A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004
Role: collaborator
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Role: lead
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Role: lead
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Role: lead
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
Role: lead
RNA-Loaded Dendritic Cell Cancer Vaccine
Role: lead
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
Role: lead
A Single-Patient Study Using AGS 006
Role: lead
An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)
Role: lead
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
Role: collaborator
All 13 trials loaded